Skip to main content

Bausch Health Companies Inc. Value Stock - Dividend - Research Selection

Bausch health

ISIN: CA0717341071 , WKN: A2JQ1X

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company is engaged in the development and commercialization of a range of generics, generic and branded products, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgery devices and aesthetic devices). It operates through two segments: developed markets and emerging markets. The Developed Markets segment focuses on the areas of dermatology, neurology, gastrointestinal diseases and ophthalmology. The Emerging Markets segment focuses primarily on branded generics, OTC products and medical devices. The pharmaceutical products include Xifaxan, Solodyn and Glumetza. OTC products include Preservision, Biotrue and Boston. Other generics include latanoprost and metronidazole. The ophthalmic products include intraocular lenses such as Akreos, enVista, Crystalens and Trulign.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Bausch Health in 'Stronger Position' for Bausch + Lomb Distribution, RBC Says

2024-04-23
Bausch Health in 'Stronger Position' for Bausch + Lomb Distribution, RBC Says

Bausch Health price target lowered by $1 at RBC Capital, here's why

2024-04-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Analysts Conflicted on These Healthcare Names: Bausch Health Companies (BHC) and Enlivex (ENLV)

2024-04-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Carl Icahn Bolsters Stake in Icahn Enterprises LP

2024-04-22
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

10 Best Healthcare Stocks to Buy Under $20

2024-04-20
In this article, we will be taking a look at the 10 best healthcare stocks to buy under $20. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Best Healthcare Stocks to Buy Under $20. Global Healthcare Outlook for 2024 As 2024 progresses, the optimism surrounding the healthcare […]

Jefferies healthcare analyst holds an analyst/industry conference call

2024-04-17
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Bausch Health put volume heavy and directionally bearish

2024-04-17
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Walgreens Boots Alliance (WBA) and Evolent Health (EVH)

2024-04-15
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Arcus Biosciences (RCUS)

2024-04-12
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Bausch Health to Announce First-Quarter 2024 Results on May 2

2024-04-11
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST ...